Skip to content
Company Analysis

Inovio Pharmaceuticals, Inc. INO

A comprehensive view of key metrics, scores, and financial health for Inovio Pharmaceuticals, Inc.

Overview of Inovio Pharmaceuticals, Inc.

INO NCM
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Micro Cap
Inovio Pharmaceuticals, Inc. (INO), is a Micro Cap company, in the Biotechnology industry, last closed at $1.42, about 0.0% overvalued vs fair value, -40.3% 1Y return, ranked 923/1145 in sector.
Metrics Rev Growth -70.0% ROE -183.5%
USD 1.42
-0.70%
(Delayed)
• Vol 90d: 106.2%
52-Week Range
Market Cap
$97.90M
Enterprise Value
$68.91M
Overall Score
View breakdown
Overall
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Good
Growth
Fair
Profitability
Weak
Health
Weak
Efficiency
Fair
Valuation
Good
Completeness: 100%
Confidence: 59%
Updated: Sep 12
Top Beats
No strong beats yet

Quick Facts

Website https://www.inovio.com
HQ Plymouth Meeting, PA
Employees 134
Fiscal year Dec 31

Next Events

Earnings Nov 10 Estimated

Fair Value Snapshot

Bear Base Bull
$-2
$-2
$-2
Current: $1.42

Engine Room Money Flow™

Micro Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$44.3M
-32.7%%
Total Revenue
$65.3K
-70%%
Net Income
$-84.9M
20.8%%
Operating Expense
$86.9M
-22.8%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

Cash Runway
6.0 months
Poor

Critical: Cash runway under 12 months

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health healthy
Strong cash conversion with minimal leakage across profit-to-cash-to-value chain.
0
Active Leaks
0/0
Improving
0
High Impact
0
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Inovio Pharmaceuticals, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
11
/100
Weak
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 3.9th percentile with high volatility suggests weak pricing power or commoditized products.
  • Elevated Debt Risk Debt serviceability is weak (score 0.17), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
5
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger

Where management spends the performance budget

Insufficient Data for Analysis

INO - Inovio Pharmaceuticals, Inc.

We have limited financial data for INO. The Growth and Profitability axes don't have enough metrics for reliable analysis.

Data Coverage by Axis

Growth
0% coverage Below threshold
Profitability
0% coverage N/A
Overall Coverage: 26.7% (Minimum 40% required)

What This Means

  • Currently at 26.7% data coverage (minimum 40% required)
  • Limited peer data available for industry benchmarking
  • Check back after quarterly or annual filings
  • Some metrics may not be applicable to this company's business model

What can you do?

  • View available sections like Moat Map or Engine Room for partial insights
  • Set up a watchlist alert to be notified when new data becomes available
  • Compare with peers in the same industry that have complete data

Two Futures

Scenario-based fair value ranges for Inovio Pharmaceuticals, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$-1.60
- - -
- upside
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000